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Abstract
Malnutrition encompassing both macro- and micro-nutrient deficiency, remains
one of the most frequent complications of alcohol-related liver disease (ArLD).
Protein-energy malnutrition can cause significant complications including
sarcopenia, frailty and immunodepression in cirrhotic patients. Malnutrition
reduces patient’s survival and negatively affects the quality of life of individuals
with ArLD. Moreover, nutritional deficit increases the likelihood of hepatic
decompensation in cirrhosis. Prompt recognition of at-risk individuals, early
diagnosis and treatment of malnutrition remains a key component of ArLD
management. In this review, we describe the pathophysiology of malnutrition in
ArLD, review the screening tools available for nutritional assessment and discuss
nutritional management strategies relevant to the different stages of ArLD,
ranging from acute alcoholic hepatitis through to decompensated end stage liver
disease.
Key words: Malnutrition; Sarcopenia; Alcohol-related liver disease; Nutritional
assessment; Nutrition support; Micronutrients
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Core tip: Malnutrition is a common complication of alcohol-related liver disease (ArLD),
which, if untreated, can adversely affect patient outcome and recovery. Prompt
recognition of nutritional depletion may identify those patients who are at higher risk of
clinical decompensation, but there are few guidelines to inform the clinical management
of these complex patients. In this article, we discuss the pathophysiology and treatment
of micro- and macro-nutrient deficiency in ArLD, and provide recommendations for the
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management of patients at different stages of their illness.
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The  World  Health  Organization  estimates  that  alcohol  abuse  accounts  for
approximately 3.3 million deaths every year[1], with a significant proportion due to
liver disease[2].  Forty-one percent of liver deaths in Europe are related to harmful
alcohol consumption[3]. Alcohol-related liver disease (ArLD) refers to a wide spectrum
of liver pathologies, including steatosis (fatty liver), steatohepatitis (characterized by a
combination of hepatic fat accumulation and inflammation), acute alcoholic hepatitis
(AAH) and liver cirrhosis[4]. It is important to understand that whilst alcohol is the
principle mediator of liver injury in many individuals with cirrhosis, it can play a
significant  contributory  role  in  the  progression  of  other  liver  diseases  such  as
hereditary haemochromatosis and non-alcoholic steatohepatitis. The component of
alcohol relating to conditions developing in such a setting are commonly described as
alcohol-contributory liver disease (AcLD). Alcohol use disorders should be sought in
all individuals presenting with chronic liver disease due to the prevalence of alcohol
abuse across the diagnostic spectrum with both ArLD and AcLD requiring a common
final  pathway of  management.  Whilst  targeted pharmaceutical  interventions are
lacking in  patients  with  alcohol-related cirrhosis[5],  sustained alcohol  avoidance
remains the cornerstone of ArLD and AcLD management and recovery[6].
Several studies have identified a strong relationship between poor nutrition and
adverse outcomes in survival, quality of life and complications of alcohol-related
cirrhosis, such as variceal bleeding, ascites, hepatic encephalopathy (HE), infection
and hepato-renal  syndrome[7-9].  Protein-energy malnutrition (PEM: Altered body
composition due to an imbalance of energy, protein and micronutrients)[10,11] is one of
the most frequent complications of harmful alcohol use and can occur at all stages of
ArLD[12,13].  Studies have shown that up to half of outpatients with alcohol-related
cirrhosis, and almost all hospitalized patients with AAH exhibit evidence of clinically
significant nutritional depletion[13-15]. Early diagnosis of malnutrition allows clinicians
to tailor therapeutic strategies to avoid potential adverse outcomes in chronic liver
disease as well as predicting those patients at higher risk of hepatic decompensation
and/or liver-related death[16].  A recent study of 363 patients admitted with AAH
reported a one-year mortality of 14% and 76%, in individuals classified with mild or
severe malnutrition respectively[17]. In contrast, nutritional supplementation has been
shown to be an effective means of improving liver function and patient survival in
AAH[18,19]. In a randomised multicentre trial of severe AAH patients, Cabré et al[20]
compared short  and long-term effects  of  steroids  and total  enteral  nutrition  via
nasoduodenal tube (providing 2000 kcal/d for 4 wk). Although short-term mortality
was no different,  the  study showed improved outcomes at  1  year  follow-up for
patients treated with total enteral nutrition (P = 0.04, intention-to-treat analysis), with
8% one-year mortality reported in the enterally fed group, compared to 37% in the
prednisolone-only group during the follow-up period, with most deaths attributed to
sepsis[20].
There  can be  little  doubt  that  the  lack of  clinical  practice  guidelines  aimed at
assessing and grading ArLD-related malnutrition accounts for the poor recognition,
diagnosis and treatment of this condition in clinical practice. The aim of this article is
to define the relevant pathophysiology, summarise modes of assessment and discuss
optimal nutritional management in different forms of ArLD.
PATHOPHYSIOLOGY OF MALNUTRITION IN ARLD
Malnutrition  in  ArLD  and  AcLD  is  multifarious  and  comprised  of  many
interdependent  elements,  but  simply  increasing  the  availability  of  energy
supplements is not enough to counteract the powerful forces that drive the catabolic
WJG https://www.wjgnet.com June 14, 2020 Volume 26 Issue 22
Kamran U et al. Management of malnutrition in ArLD
2917
state. Here we explore some of the elements that contribute to the condition (Figure
1).
Poor appetite
Loss  of  appetite  and  reduced  food  desire  is  related  to  the  upregulation  of
inflammatory  cytokines  and appetite  regulators  in  both  acute  and chronic  liver
disease. In patients with alcohol-related cirrhosis, tumour necrosis factor (TNF-α) and
leptin (an appetite-regulating hormone secreted by adipose tissue) levels increase[21-23]
which diminish appetite and cause early satiety. Increased TNF-α levels in AAH and
alcohol-related  cirrhosis  upregulate  secondary  inflammatory  cytokines  such  as
interleukin (IL)-1b, IL-6 and IL-8, which increase appetite suppression and cause
selective nutrient avoidance[24,25]. Whilst cytokines may act as a regulatory component
of appetite in health, in disease states their dysregulation is a major contributor to the
cachexia seen in all forms of acute and chronic disease[26]. Cytokines can also mediate
their actions on appetite via neural and humoral effects and TNF-α further modulates
metabolism by directly acting on the central nervous system to alter the release of
neurotransmitters,  which slow gut  motility  and gastric  emptying[27].  Anorexia is
worsened  by  physical  symptoms  of  discomfort  (nausea,  bloating  and  fatigue),
dysgeusia and the mechanical effects of large ascites[28].  These factors may impact
upon the food choices of patients and affect both the quality and quantity of nutrition
as a result.
Intestinal dysfunction and malabsorption
Alcohol is absorbed by diffusion in the stomach and, to a lesser degree the duodenum
and jejunum. Whilst acute and excessive alcohol consumption can cause gastric and
duodenal erosions and villous-predominant epithelial loss in the upper jejunum[29], the
effects  of  chronic  alcohol  consumption  on  the  intestinal  mucosa  are  poorly
understood. They may include intestinal  fibrosis and overgrowth of aerobic and
anaerobic  microorganisms  which  contribute  to  functional  and  morphological
abnormalities of the small bowel[30].  Gerova et al[31]  reported a higher frequency of
small  intestinal  bacterial  colonisation  in  patients  with  ArLD,  with  the  changes
occurring independently of the stage of liver dysfunction suggesting that the direct
effect of alcohol on gut motility and immunity creates a permissive microenvironment
for small bowel overgrowth at these sites.
In addition to changes in the gut microbiome, chronic alcohol ingestion can lead to
a reduction in the adhesion of epithelial cell tight junctions[32] resulting in increased
intestinal permeability, bacterial translocation and consequential increases in pro-
inflammatory cytokines and lipopolysaccharides[33].  Chronic alcohol consumption
impairs gut motility and alcohol-induced chemical gastritis delays gastric emptying,
both of which significantly increase the oro-caecal transit time[34] leading to impaired
absorption of nutrients. Furthermore, alcohol is an important risk factor for chronic
pancreatitis  and  pancreatic  exocrine  insufficiency  (PEI)  which  can  exacerbate
malabsorption[35].
Impaired energy metabolism
Resting energy expenditure (REE) is  the amount of energy an individual uses to
perform vital organ functions free of activity and digestion. REE can be calculated
using the predictive formula of Harris-Benedict[36]  however its calculation can be
unreliable in patients with altered body composition (by misconstruing the weight of
extracellular fluid as dry body mass and overestimating the caloric requirements in
cirrhotic patients with ascites). Indirect calorimetry is not subject to this limitation as it
measures REE without reference to body composition by basing its calculation on
oxygen consumption and carbon dioxide production[37]. Hypermetabolic states (REE >
110%)  commonly  occur  in  ArLD,  where  approximately  20%  of  patients  exhibit
features of hyper-metabolism[38] which accelerates calorific expenditure and promotes
a negative nitrogen balance by increasing urinary and faecal nitrogen losses[39].  In
heavy  drinkers’,  alternative  alcohol-metabolic  pathways  are  engaged following
excessive alcohol consumption due to the zero-order kinetics of alcohol metabolism.
The ensuing increase in acetaldehyde production (a toxic metabolite of alcohol) puts
stress on microsomal re-oxidation pathways which utilise more oxygen and ATP[40] to
recover nicotinamide adenine dinucleotide, thereby perpetuating the hyperdynamic
metabolism by increasing energy utilisation.
AAH is a classical example of the alcohol-induced hypermetabolic state[41,42]. The
accelerated catabolism typically seen in these patients is a composite of reduced oral
energy intake with food as the individual becomes dependent on the calorific value of
alcohol to provide their basal metabolic expenditure and subsequently becomes more
protein-calorie deplete. Many patients reduce their alcohol intake before presenting
with  clinical  manifestations  of  AAH[43]  thus  compounding  the  calorie  debt  and
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Figure 1
Figure 1  Schematic illustration of causes and mechanisms of malnutrition in alcohol related liver disease. ArLD: Alcohol related liver disease; IL: Interleukin;
TNF: Tumor necrosis factor.
catalysing a chain of events leading to the establishment of a chemical and metabolic
liver injury characterised by hepatitis and the sudden onset of jaundice and synthetic
failure. It is pertinent that the proven treatments for AAH include alcohol cessation
and nutritional therapy with high protein and calorie supplementation.  Another
driver  of  hyper-metabolism  is  systemic  low  grade  endotoxaemia[44],  driven  by
bacterial translocation, which can lead to upregulation of the sympathetic nervous
outflow and worsening of the hypermetabolic state. This results in clinical features
such as fever, tachycardia, hyperglycaemia and muscle wasting[45,46]. In such patients,
the accumulation of ascites further increases REE under indirect colorimetry testing
due to the energy expense required to maintain the large fluid volumes at  body
temperature. Improvements in energy expenditure are seen in patients after large
volume paracentesis[47].
EFFECT OF ALCOHOL ON MACRO AND MICRONUTRIENTS
Carbohydrate
Excessive  alcohol  intake  over  a  prolonged  period  results  in  impaired  insulin
resistance and increased cardiovascular  morbidity  and mortality[48,49].  In  chronic
alcohol  consumption  glycogen  stores  of  the  liver  are  depleted,  whilst  in  acute
episodes of heavy alcohol consumption (binge drinking) gluconeogenesis is inhibited
and hepatic glycogenolysis stimulated to prevent hypoglycaemia. Therefore, whilst in
a healthy individual acute alcohol consumption is unlikely to cause changes in the
euglycemic state, in patients with chronic liver disease acute alcohol ingestion may
precipitate hypoglycaemia[50,51].
Proteins and muscle
Low to moderate doses of alcohol have little to no effect on muscle protein balance
but acute ingestion of large doses of alcohol and chronic alcohol abuse causes changes
to both whole-body and tissue-specific protein metabolism by increasing nitrogen
excretion[52]. Myopathy is a common complication of chronic alcoholism and is the
result of a prolonged imbalance between muscle protein growth and breakdown[53,54].
Lipids
The liver plays a central role in lipid metabolism which follows a complex network of
reactions  and  interplay  of  hormones,  nuclear  receptors,  intracellular  signalling
pathways and transcription factors. Free fatty acids (FAs) are synthesised by the liver
from glycolytic pathways and are directly mobilised from the gut and adipose tissue.
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Alcohol inhibits FA oxidation pathways (by decreasing expression of several PPARα-
regulated genes)[55]  and increases  esterification  of  FAs  resulting  in  an  increased
accumulation of intrahepatic triglyceride[56]. Alcohol also affects FA export from the
liver by suppressing microsomal triglyceride transfer protein, as seen in livers of
ethanol  fed  animals,  which  is  required  for  the  assembly  of  very  low  density
lipoprotein prior  to  export[57].  The result  is  intrahepatic  fat  accumulation,  which
ultimately progresses to cirrhosis as a result of iterative cycles of injury and cell-death
associated with sustained alcohol excess.
B-Vitamin and folate
Thiamine (vitamin B1)  serves  as  a  cofactor  for  the  enzymes involved in  glucose
metabolism. Thiamine deficiency results in decreased activities of these pathways
which can result in reduced ATP synthesis leading to cell damage and cell death.
Chronic alcoholism leads to thiamine deficiency as a result of inadequate nutritional
intake and decreased absorption of thiamine from the gastrointestinal tract[58]. Careful
reintroduction of diet may need to be considered if refeeding syndrome is a concern,
as  the  sudden increase  in  carbohydrate  consumption causes  a  shift  from fats  to
carbohydrate  for  energy  production,  increasing  the  demand  for  thiamine  and
compounding any deficiency by further depleting stores[59]. Wernicke encephalopathy
is an acute neurological crisis which results from exhausted thiamine stores and is
characterised by the clinical triad of encephalopathy, oculomotor dysfunction, and
gait ataxia. If  left untreated individuals can develop permanent neuropsychiatric
complications such as Korsakoff’s syndrome which is typified by a marked deficit in
anterograde  and  retrograde  memory,  apathy,  an  intact  sensorium,  but  relative
preservation of long-term memory and other cognitive skills. Folate deficiency is also
seen in these patients due to reduced dietary intake, intestinal malabsorption, reduced
liver uptake, storage and increased urinary excretion[60].  Deficiencies in folate can
cause defective DNA synthesis and repair which may manifest as macrocytic anaemia
and muscle dysfunction.
Vitamin A
Chronic alcohol  consumption and jaundice cause vitamin A levels  to fall[61].  The
metabolism of vitamin A is similar to alcohol metabolism in the human body as they
both involve oxidative pathways and are therefore vulnerable to alterations in the
basal redox-state of the liver[62]. Alcohol dehydrogenase activity and cytochrome 2E1
negatively affect retinoid homeostasis[63] and chronic alcohol consumption leads to
depletion of hepatic and plasma retinoid levels and retinoid binding proteins[64,65].
Alcohol is also believed to inhibit the cleavage of β-carotene, a dietary pro-vitamin A
carotenoid[66].  Vitamin A deficiency can lead to the clinical  presentation of  night
blindness.
Vitamin C
Various mechanisms, in addition to dietary insufficiency, have been postulated to
account for vitamin C deficiency in the context of chronic alcohol consumption[67].
Alcohol-induced  enterocyte  toxicity  leads  to  intestinal  malabsorption  and
hepatotoxicity which inhibit hepatic transformation of various vitamins (including
vitamin C) to their active metabolites[68]. The imbalance in vitamin C is exacerbated by
increased urinary ascorbic acid excretion following episodes of alcohol excess[69]. Some
studies  suggest  that  pre-treatment  with  vitamin C significantly  enhances  blood
ethanol  clearance,  possibly as  a  result  of  its  ability  to  supply peroxide and thus
allowing catalase  to  contribute  to  ethanol  oxidation[70].  Clinical  manifestation of
vitamin C deficiency is  namely  scurvy and can present  as  poor  wound healing,
gingival swelling, gum bleeding, loss of teeth and mucocutaneous petechiae; late
disease may be life-threatening with anasarca, haemolysis and jaundice[71,72].
Zinc
Zinc is absorbed via metal binding transcription factors and plays a key role in the
regulation of gene expression. In alcohol-fed mice, alcohol disrupts gut permeability
and increases oxidative stress, predominantly at the level of distal small bowel which
interferes with zinc homeostasis and leads to reduced ileal zinc concentrations[73].
Animal studies have shown that zinc supplementation preserves intestinal integrity
and  prevents  endotoxaemia,  leading  to  inhibition  of  endotoxin-induced  TNF-α
production in the liver under both acute and chronic conditions of alcohol exposure[74].
In addition to reduced enteric absorption and increased urinary excretion of zinc,
patients with alcohol-related cirrhosis often have diets lacking in protein and zinc,
with  zinc  deficiency  a  common  (and  easily  rectified)  cause  of  dysgeusia.  Zinc
deficiency may manifest as acrodermatitis, anorexia, hypogonadism, altered immune
function, poor wound healing, impaired night vision, diarrhoea, impaired mental
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function and portal systemic encephalopathy[75,76].
Magnesium and selenium
Magnesium is  the second most  abundant  micronutrient  in  the human body and
deficiency is almost universal in individuals with high levels of alcohol consumption
and/or liver disease. It is a critical determinant of metabolism, acting as a co-factor in
more than 300 enzymatic reactions involved in protein and nucleic acid synthesis and
energy metabolism. Alcohol increases the urinary excretion of magnesium and total
body stores of magnesium are depleted in nearly all patients with alcohol-related
cirrhosis[77]. Further insensible losses occur as a result of alcohol-related diarrhoea,
vomiting  and  concurrent  use  of  drugs  such  as  diuretics  and  aminoglycosides.
Hypomagnesemia  predisposes  to  metabolic  bone  disease,  cardiovascular  co-
morbidities  and  is  associated  with  seizure,  depression  and  neuromuscular
abnormalities[78,79] (Table 1).
The interactions of divalent cation deficiencies such as selenium and magnesium
are poorly understood but seem to play a key role in the immune-paresis seen in
alcohol-related cirrhosis. Selenium deficiency is common in alcohol-dependency[80,81]
and proportionate to disease stage and increased levels of pro-inflammatory cytokines
which  play  a  role  in  liver  injury  and  fibrosis.  Current  evidence  suggests  that
micronutrient metabolism is impaired in decompensated liver disease and that by
replacing these elemental deficiencies, clinicians may be able to counteract some of
the immune-paresis  and mood disorders  commonly seen in  these malnourished
states[82,83].
CLINICAL CONSEQUENCES OF MALNUTRITION ON ARLD
Malnutrition and sarcopenia are important determinants of prognosis and survival in
cirrhotic patients[84,85]. A South Korean study of patients with liver cirrhosis (62% with
ArLD)  showed  that  the  presence  of  sarcopenia  was  associated  with  increased
mortality [hazard ratio (HR) 2.27, 95% confidence interval (CI): 1.17-4.40, P = 0.015]
and that accelerated loss of skeletal muscle was independently associated with poor
outcome (HR 0.94, 95%CI: 0.90-0.99, P = 0.013)[86]. Poor nutrition increases the risk of
complications and decompensation in liver disease patients[87].  Moreover, because
muscle acts as an alternative site of ammonia detoxification[88] prospective studies in
cirrhotic  patients  have  shown that  both  overt  and minimal  HE are  increased in
patients with muscle depletion[89]. Nutrition has also been shown to have significant
impact on ascites. Vidot et al[90] demonstrated that aggressive nutritional support in
the form of supplemental tube feeding (for 7 ± 1 wk) significantly reduces ascites
formation and the requirement for paracentesis (P < 0.001) in malnourished patients
who fail to respond to standard oral nutrition.
Cirrhosis and malnutrition produce an acquired state of immune paresis which
negatively impacts upon patient recovery and survival[91,92]. Protein malnutrition is an
independent risk factor for infection and sepsis in hospitalized patients with cirrhosis,
and septic episodes in these individuals are associated with higher in-hospital and
post discharge mortality at six months (50% vs  11% respectively, P  < 0.001)[93].  In
patients with ArLD, the presence of sarcopenia (as recorded by the skeletal muscle
index)[94] is independently associated with an increased likelihood of an individual
being removed from the transplant waiting list due to clinical deterioration (HR 1.9,
95%CI: 1.2-3.1, P = 0.01) and a higher likelihood of waiting list death[95]. The impact of
malnutrition and sarcopenia on post-transplant outcomes were reported by Kalafateli
et al[96] using the Royal Free Hospital-Global Assessment (RFHGA) tool and the L3
psoas muscle index (L3PMI) to assess nutritional status. Severe malnutrition, defined
as RFHGA score 3, was associated with a prolonged intensive care stay i.e.,  > 5 d
(odds ratio=7.46, 95%CI: 1.57-35.43) whilst low L3PMI was an independent predictor
for  a  hospital  stay  more  than  twenty  days  and  higher  12-mo  mortality[96].  The
diagnosis and management of sarcopenia is therefore of paramount importance in the
initial (and subsequent) assessment of liver-disease patients receiving clinical care.
NUTRITIONAL SCREENING TOOLS
There is no gold standard for assessment of malnutrition in liver disease and none
specifically designed for patients with ArLD, but there are a number of screening
tools[97]  that have been developed to assess malnutrition risk, although most lack
external validation. The Liver Disease Undernutrition Screening Tool[98] is a 6-question
nutrition screening tool which was found to accurately identify malnutrition (93%) in
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Table 1  Effect of alcohol on nutrients
Nutrients Effect of alcohol intake Results
Carbohydrate Acute alcohol intake Inhibits gluconeogenesis; stimulates
hepatic glycogenolysis
Hypoglycaemic; hyperglycaemic
Chronic alcohol intake Inhibits lactate stimulated
gluconeogenesis; carbohydrate rich
food taken with alcohol
Hyperlactatemia; delayed
paradoxical hypoglycaemic state
Proteins Acute and chronic alcohol intake Increases nitrogen excretion;
imbalance between protein growth
and breakdown
Muscle wasting and myopathy
Lipids Acute and chronic alcohol intake Inhibits β-oxidation and increases




Thiamine Chronic alcohol intake Inadequate nutritional intake
Decreased absorption
Wernicke Korsakoff syndrome
Folate Chronic alcohol intake Reduced dietary intake; intestinal
malabsorption; reduced liver uptake,
storage; increased urinary excretion
Macrocytic anaemia; muscle
dysfunction
Vitamin A Chronic alcohol intake Inhibit the cleavage of β-carotene, a
dietary pro-vitamin A carotenoid
Xerophthalmia and night blindness
Vitamin C Chronic alcohol intake Intestinal malabsorption;
hepatotoxicity inhibits hepatic
transformation to their active
metabolites
Scurvy and poor wound healing
Zinc Chronic alcohol intake Disrupts gut permeability; decreases
ileal -zinc concentration; increased
accumulation of reactive oxygen
species and plasma endotoxin levels
Acrodermatitis; anorexia;
hypogonadism; altered immune
function; poor wound healing;
impaired night vision; diarrhoea;
impaired mental function and portal
systemic encephalopathy






patients with liver cirrhosis although it has not been studied in longer-term outcomes.
Whereas the Royal Free Hospital Nutritional Prioritisation Tool (RFH-NPT)[99] has
been adapted to  account  for  fluid overload.  RFH-NPT is  user  friendly,  quick  to
complete and is a good predictor of clinical deterioration. Given the high prevalence
of  malnutrition  and  sarcopenia  in  alcohol-related  cirrhosis,  all  patients  should
undergo  nutritional  screening  at  the  point  of  presentation,  ideally  using  a
standardised screening tool such as the RFH-NPT[100].
Body mass index (BMI) is often distorted in patients with chronic liver disease by
fluid retention states like anasarca or ascites. Moreover, sarcopenic-obesity is another
entity characterised by excessive fat and poor muscle mass and function[101]. In these
settings, BMI proves to be an inadequate metric by which to predict complications
and should be used in combination with objective measures of muscle mass and
strength.
Muscle  function tests  are  an important  component  of  assessing nutrition risk.
Hand-grip strength (HGS) has been well validated and is commonly used in clinical
practice to record strength and muscle capacity[102].  A dynamometer measures the
strength exerted by a patient’s non-dominant hand, the results of which are compared
to  tables  of  normal  values  based  on  sex  and  age  of  healthy  volunteers.  It  is  an
inexpensive,  easily replicated test  and can be completed at  the bedside or clinic.
Observational studies have shown that HGS is strongly correlated with Child-Pugh
score and can predict the risk of short-term morbidity in patients with alcohol-related
cirrhosis[103]. Moreover, HGS operates as a predictive tool for complications of cirrhosis
and muscle function testing can be used as a predictive determinant of HE[97]. Mid-
arm circumference and triceps skinfold (TSF) are used to calculate skeletal muscle
mass (mid-arm muscle circumference, MAMC) and it has been demonstrated that
MAMC, TSF, HGS are accurate predictors of pre-transplant morbidity[97]. Both HGS
and MAMC should be routinely monitored in clinic as they provide a good indication
of nutritional state and are reliable predictors of clinical deterioration. Muscle strength
(HGS) commonly falls before muscle mass depletes, and strength can reduce without
a change to muscle mass, thus making HGS a useful dynamic predictor of nutritional
decline[102] (Figure 2).
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Figure 2
Figure 2  Assessment of anthropometrics. MAC: Mid-arm circumference; TSF: Triceps skinfold skinfold; MAMC: Mid-arm muscle circumference.
NUTRITIONAL SUPPORT IN SPECIFIC LIVER DISEASE
SETTINGS
AAH
Early introduction of oral  nutrition support improves survival for malnourished
individuals with AAH although the data remains conflicted. A meta-analysis[104] of 7
randomized controlled trials demonstrated no mortality benefit with supplemental
nutrition but the studies were under-powered. Cabré et al[20] found that 6-mo mortality
increased in those whose overall calorie intake was lower than 21.5 kcal/kg per day,
suggesting that additional oral nutritional supplementation in such individuals would
improve  survival.  A  daily  energy  target  of  35-40  kcal/kg  is  recommended,  but
refeeding syndrome needs to be considered as it can be encountered in extreme cases.
Intensive pre-supplementation of vitamins B and C with thiamine (e.g., Pabrinex®) is
necessary to prevent acute depletion and the development of Wernicke’ syndrome.
Refeeding syndrome can occur when there are shifts  in fluid and electrolytes  in
patients who are malnourished after their nutritional intake increases and is more
common with oral nutritional supplements or tube feeding as opposed to oral intake
alone[105].  In advanced liver  disease,  PEM becomes more prevalent  and the main
challenge is to minimise muscle catabolism[106]. If AAH develops on the background of
cirrhosis, energy and protein requirements are likely to increase. In practice a patient’s
estimated energy requirements may increase to 40 kcal/kg per day if body weight is
low and nutritional intake is negligible.
Decompensated alcohol-related cirrhosis
In patients with decompensated cirrhosis due to ArLD additional nutrition support is
almost always indicated, particularly in patients with ascites. It is important to avoid
prolonged fasting periods to minimise the breakdown of muscle and adipose stores
for use as a metabolic fuel, and a regular 2-3 hourly eating pattern including a bed-
time snack can support this. Whilst adjustments to the frequency of energy delivery
are an effective means of preventing accelerated loss of skeletal fat mass by inhibiting
gluconeogenesis; patients who graze constantly throughout the day protect muscle
but may not consume enough calories to preserve adipose stores and additional
calories may be required to prevent adipose wasting[106].  Energy requirements in
compensated cirrhosis are therefore estimated at 25-30 kcal/kg per day and 30-35
kcal/kg per day in decompensated cirrhosis. For obese patients (BMI > 30 kg/m2)
energy requirements  are estimated at  around 25 kcal/kg per day (Figure 3).  All
requirements should be based on estimated dry body weight and estimated BMI.
Naso-gastric (NG) or naso-jejunal (NJ) feeding is clinically indicated when energy
and/or  protein  requirements  cannot  be  met  through  oral  intake  alone.  Other
indications for initiating NG/NJ feeding in liver cirrhosis include early satiety from
ascites, refractory ascites, optimisation of energy and protein requirements, or chronic
vomiting.  Kearns  et  al[107]  assigned a  control  group with AAH with concomitant
cirrhosis  to  receive  standard  oral  intake  whilst  another  group  received  enteral
nutrition in addition to 40 kcal/kg a day and 1.5 g/kg per day protein orally. The
enterally fed group received 200% more energy than the controls and showed an
improvement in nitrogen balance, serum albumin and HE (P ≤ 0.02) after 3 wk. Whilst
this  study  demonstrated  a  short-term  improvement  in  nutritional  status  and
reduction in liver-related adverse events, the small sample size and cross-sectional
nature of this study limited assessment of longer-term outcomes. Other studies have
highlighted the risks of intensive tube feeding in cirrhosis and retaining placement of
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Figure 3
Figure 3  Assessment and management of malnutrition across the stages of alcohol-related liver disease. Summary of recommendations for protein and
energy intake, optimising nutrition intake across different stages of alcohol-related liver disease and in special considerations including ascites, hepatic
encephalopathy, malabsorption and micronutrient deficiency. BMI: Body mass index; MAC: Mid-arm circumference; TSF: Triceps skin fold; MAMC: Mid-arm muscle
circumference; HGS: Hand grip strength; SIBO: Small intestinal bacterial overgrowth.
short-term  feeding  tubes  in  situ  can  be  a  challenge,  particularly  in  confused
patients[18,108].
Protein requirements in the presence of ascites and/or oedema are particularly
high due to the degree of protein loss encountered, particularly in those patients
requiring frequent or large-volume paracentesis. A minimum protein intake of 1.2-1.5
g/kg of dry body weight/day is recommended for individuals with stable muscle
mass[100] and in these individuals concentrated high protein supplements (60-125 mL
containing 18-20 g protein) are used to support nutritional intake as they are often
better tolerated, particularly in the presence of poor appetite, early satiety and fatigue.
It is important to tailor sip feeds to individual needs (i.e., protein deficit, taste, early
satiety and appetite) and when oral supplements are poorly tolerated, supplementary
tube  feeding  can  be  initiated.  Patients  with  high  volume recurrent  ascites  with
evidence  of  muscle  loss  commonly  require  1.5-2  g/kg protein  a  day.  Guideline
recommendations  for  dietary salt  intake are  conflicting;  some recommend strict
reduction of  sodium intake  whilst  others  acknowledge that  over-restriction  can
increase  the  risk  of  PEM  due  to  food  aversion.  In  practice,  aggressive  sodium
restriction should be avoided wherever possible as the resulting diet is unpalatable
and leads to avoidance of protein-rich foods. Patients should not be encouraged to
restrict their salt intake below 60 mmol per day and we advocate a “no-added salt”
diet with minimisation of pre-prepared foods such as crisps, tinned soups, microwave
meals etc.[100,109].
HE has been observed to occur more frequently in the presence of sarcopenia and
for this reason protein restriction is not recommended to support management of HE.
There  is  a  well-recognised  association  between  muscle  depletion  and  negative
nitrogen balance with worsening liver decompensation and subsequent complications
such as HE[109,110] and it is vitally important that clinical care plans limit the impact of
PEM and muscle wasting by avoiding catabolism through encouraging small frequent
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meals, eating regularly and optimising protein intake (minimum of 1.2 g/kg per day)
to support muscle mass[110]. Enteral (NG) tube feeding should be considered in the
presence of advanced HE[111] particularly when sufficient oral intake is reduced or not
feasible[100].  Nursing  staff  must  be  experienced  in  the  management  of  tube-feed
systems  and  aware  of  the  increased  risks  of  aspiration  that  can  occur  in
encephalopathic patients. Great care should be taken to ensure that the tube is re-
inserted correctly when it is displaced and the use of a bridle may be considered (if
there is no risk of bleeding) to prevent the tube from being withdrawn inadvertently.
Varices should not preclude enteral tube placement unless there are signs of active
bleeding[112].  Despite the risks of tube-supported enteral feeding in liver patients,
failure to implement adequate nutritional support in such cases will only lead to
accelerated sarcopenia and a worsening of the patient’s clinical condition. The risk-
benefit analysis in such patients needs to be carefully considered and patient choice
always considered.
Alcohol-related malabsorption
Steatorrhea (symptoms and signs including nausea, pale/yellow coloured, oily and
foul-smelling stools) needs to be identified promptly to enable effective management.
PEI should always be considered in patients with ArLD using appropriate testing
such as faecal elastase measurement as there is a high prevalence amongst these
individuals[113].  Treatment  with  pancreatic  enzyme  replacement  therapies  e.g.,
CREON™, PANCREX-V™ must be initiated at an early stage with education about
dose titration to increase compliance. When jaundice is present, biliary malabsorption
needs to be considered as patients can manifest symptoms indistinguishable from PEI.
The  choice  of  feed  is  crucial  in  cholestatic  patients  and  low-fat  feeds  such  as
Meritene™ and Renapro Powder™ (orally) and Nutrison Peptisorb™ and Peptamen
HN™ (enterally) should be chosen over high-lipid counterparts (Fortisip Compact
Protein™ and Ensure Twocal™) to reduce the risk of exacerbating nutritional and
trace element depletion. Management primarily involves reducing dietary fat intake
although  there  is  little  consensus  as  to  what  constitutes  a  low-fat  diet.  Food
frequencies should be assessed, and creamy or fried foods discouraged. Fat-soluble
vitamins  (vitamins  A,  D,  E  and  K)  must  be  supplemented.  If  steatorrhea  is  left
untreated it can exacerbate malnutrition through reduced food intake (food aversion),
dysgeusia and vitamin and mineral deficiencies.
Small intestinal bacterial overgrowth
The symptoms of small intestinal bacterial overgrowth (SIBO) include diarrhoea,
steatorrhea, chronic abdominal pain, bloating and flatulence although some patients
may be asymptomatic. It is commonly diagnosed via hydrogen or methane breath
testing and treatment usually requires a course of non-absorbed antibiotics such as
rifaximin or neomycin. One meta-analysis[114] identified a potential role for the use of
probiotics, prebiotics and symbiotics - concluding that probiotics were better tolerated
than lactulose, improved SIBO and the management of minimal HE [risk ratio (RR)
0.40,  95%CI:  0.32-0.50,  P  < 0.001] however lactulose remained the more effective
treatment for overt HE (RR 0.34, 95%CI: 0.24-0.47, P < 0.0001). It is unlikely that the
use of prebiotics could be sustained in decompensated patients, but in compensated
disease this remains an area of interest. Moreover, since non-absorbed rifamycin-
based therapies for HE has become widely available, it will be interesting to see how
the use of antibiotic therapies for HE affects the prevalence of both overt and covert
SIBO in cirrhosis.
Alcohol induced glycaemic impairment
Close monitoring of glycaemic control (particularly in patients with HE) is key to
preventing  hypo-and  hyperglycaemia,  especially  in  the  presence  of  diabetes.
Alongside prescribed oral hypoglycaemic medication or insulin therapies, foods and
fluids high in sugar should be avoided but it is imperative not to remove dietary
carbohydrates  altogether  as  this  can provoke further  catabolic  injury.  Avoiding
prolonged fasting with 2-3 hourly eating patterns, modifying the carbohydrate load
and replacing it with higher protein sources is often effective. Tight glycaemic control
can also reduce the risk of delayed-gastric emptying driven by hyperglycaemia which
may cause nausea, vomiting, abdominal pain or discomfort. If suspected, this can be
confirmed with gastric emptying scintigraphy. Diabetes should be routinely screened
if PEI is present, particularly as pancreatic β cell damage in ArLD is common[115] and it
should be noted that the use of haemoglobin as a direct marker of glycaemic control
may be inaccurate in the context of anaemia or recent blood transfusions and must be
interpreted with caution.
Micronutrient supplementation
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It is not known if replacing micronutrients prevents complications in decompensated
cirrhosis  or  reduces  sepsis  in  ArLD,  but  vitamins  and  trace  elements  must  be
corrected  at  presentation.  If  vitamin  D  deficiency  is  confirmed,  this  should  be
corrected with a vitamin D loading dose followed by maintenance therapy[116,117].
Suspected or confirmed deficiencies of vitamins A, E and/or K should be corrected
using supplements, but in coagulopathic patients vitamin injections should not be
given intramuscularly. Whilst there is no consensus regarding the replacement or
supplementation of zinc, selenium or magnesium in cirrhosis we recommend that in
stable outpatients trace elements are supplemented daily using an oral multi-vitamin
such  as  forceval  with  additional  folic  acid,  zinc,  vitamin  D  and  glutathione
supplements provided as necessary[118]. In critically ill patients these elements should
be  supplemented  parenterally  where  possible  and  enterally  via  an  NG  tube  if
possible[119].  Selenium should be given as a loading dose and then provided as a
regular supplement whilst magnesium levels can be supplemented as the biochemical
values demand. Zinc is commonly given as a zinc salt (e.g., zinc acetate) and ArLD
patients with overt HE who are admitted to intensive care can be provided with a 3-5
d course of intravenous L-ornithine L-aspartate to optimise ammonia scavenging[120].
CONCLUSION
Nutritional  assessment  and  management  of  patients  with  ArLD  is  made  more
complex  by  the  number  of  pathogenic  mechanisms  involved  in  the  clinical
deterioration  of  patients.  Nutritional  and  trace  element  depletion  is  commonly
associated with ArLD and patients may rapidly develop features of  severe PEM
unless  nutritional  management  strategies  are  initiated  promptly.  Moreover,
complications such as nutritional  immuno-paresis,  sarcopenia and frailty can be
difficult to reverse once they are established. Malnutrition and sarcopenia are strongly
associated with the development of complications of cirrhosis and poor nutrition
remains a strong predictor of both short and medium-term survival. Notwithstanding
that, reversal of energy and protein deficits in both AAH and alcohol-related cirrhosis
improve  patient  outcomes  by  improving  function  and  physical  condition  and
reducing  mortality  and  morbidity.  In  that  context  it  is  important  for  clinicians
managing such patients to have a good working knowledge of nutritional therapies
specific for liver disease so treatments can be started swiftly and applied in a scientific
manner.
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